RJA
ARIA

Raymond James & Associates’s Ariad Pharmaceuticals Inc ARIA Stock Holding History

Raymond James & Associates’s Portfolio ARIA Stock Details ARIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-18,973
Closed -$260K – 3444
2016
Q3 		$260K Sell
18,973
-31,099
-62% -$312K ﹤0.01% 2711
2016
Q2 		$370K Sell
50,072
-555
-1% -$4.16K ﹤0.01% 2278
2016
Q1 		$324K Buy
+50,627
New +$284K ﹤0.01% 2283
2015
Q3 		– Sell
-32,735
Closed -$271K – 2448
2015
Q2 		$271K Buy
+32,735
New +$289K ﹤0.01% 2308

Other funds holding ARIA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Raymond James & Associates's ARIA Position: Q4 2016 in Review

Raymond James & Associates sold out of Ariad Pharmaceuticals Inc (ARIA) in Q4 2016, closing a stake of 18,973 shares — an estimated $260K sold.

Raymond James & Associates first reported a position in ARIA in Q2 2015 and held it in 4 quarters. The position peaked at $370K in Q2 2016. 200 funds tracked by Wall St. Rank hold ARIA as of Q4 2016.

  • Raymond James & Associates reported no remaining Ariad Pharmaceuticals Inc position as of Q4 2016 after selling out during the quarter.
  • Raymond James & Associates sold 18,973 Ariad Pharmaceuticals Inc shares in Q4 2016, an estimated $260K.
  • Raymond James & Associates first reported a position in Ariad Pharmaceuticals Inc in Q2 2015 and held it in 4 quarters.
  • Raymond James & Associates's Ariad Pharmaceuticals Inc position peaked at $370K in Q2 2016.
  • 200 funds tracked by Wall St. Rank held Ariad Pharmaceuticals Inc as of Q4 2016.

Based on Raymond James & Associates's 13F filing for Q4 2016, filed 14 Feb 2017.